Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Yamawaki (Tokyo, Japan), R. Tsuzuki (Tokyo, Japan), S. Soeda (Tokyo, Japan), O. Katsube (Tokyo, Japan), Y. Kono (Tokyo, Japan), M. To (Tokyo, Japan), Y. To (Tokyo, Japan). Mepolizumab as a steroid-sparing agent for eosinophilic granulomatosis with poliangiitis: a case series. 4253

Member's Comments

No comment yet.

Related content which might interest you: Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis Source: ERJ Open Res, 6 (1) 00311-2019; 10.1183/23120541.00311-2019 Year: 2020 Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis Source: ERJ Open Res, 6 (4) 00451-2020; 10.1183/23120541.00451-2020 Year: 2020 Fatal haemoptysis in a case of lymphomatoid granulomatosis treated with rituximab Source: Eur Respir J 2006; 27: 644-646 Year: 2006 Anti-IL5 and anti-IL5Ra therapy for clinically significant bronchiectasis with eosinophilic endotype: a case series Source: Eur Respir J, 55 (1) 1901333; 10.1183/13993003.01333-2019 Year: 2020 Wegener's granulomatosis after Montelukast in patient not receiving systemic steroid treatment Source: Eur Respir J 2002; 20: Suppl. 38, 65s Year: 2002 Frequency of eosinophilic granulomatosis with polyangiitis in Europe by meta-analysis Source: Virtual Congress 2020 – Prevalence and incidence of chronic lung diseases Year: 2020 ANCA-negative eosinophilic granulomatosis with polyangiitis (EGPA) relatead to sirolimus-eluting stent Source: International Congress 2015 – Chronic airway disorders: miscellaneous aspects Year: 2015 Effectiveness of rituximab (RTX) therapy in recurrent granulomatosis with polyangiitis (GPA) Source: International Congress 2016 – New and old therapies for chronic lung diseases Year: 2016 New biomarkers for early diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) Source: International Congress 2017 – Techniques to treat asthma Year: 2017 Eosinophilic granulomatosis with polyangiitis Source: Eur Respir Monogr 2022; 95: 177-192 Year: 2022 Eosinophilic granulomatosis with polyangiitis Source: Eur Respir Monogr 2019; 86: 188-209 Year: 2019 Granulomatosis with polyangiitis (Wegener&s) Source: Eur Respir Mon 2011; 54: 1-14 Year: 2011 A case of Wegener granulomatosis that mimics metastatic pulmonary tumor and progresses with eosinophilia Source: Annual Congress 2007 - Granulomatous lung diseases including sarcoidosis Year: 2007 Twelve month outcomes with Reslizumab treatment of Eosinophilic Granulomatosis with Polyangiitis Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Aerosolized tobramycin in patients with Wegener's granulomatosis Source: Eur Respir J 2001; 18: Suppl. 33, 138s Year: 2001 Different disease subtypes in allergic eosinophilic granulomatosis with polyangiitis (EGPA) Source: Annual Congress 2013 –Clinical management of orphan lung diseases Year: 2013 Biologics for eosinophilic granulomatosis with polyangiitis Source: Short video statement 2020 Year: 2020 Immunoglobulin G4-related pneumonitis and myositis: an atypical presentation of an atypical case. Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Horner‘s syndrome in Wegener‘s granulomatosis: case report Source: Eur Respir J 2007; 30: Suppl. 51, 87s Year: 2007 Relapsing necrotising sarcoid granulomatosis in a young patient Source: Eur Respir J 2007; 29: 816 Year: 2007